Jan Schmidt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jan Schmidt has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Markus W. Büchler
Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany
3 shared publications- Arianeb Mehrabi
Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany
2 shared publications - Jürgen Weitz
Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany
2 shared publications - Peter Schemmer
Departments of General Surgery
2 shared publications Anja Wild
Department of Surgery, Philipps University, Marburg, Germany
1 shared publicationBruno M. Schmied
Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany
1 shared publication
Latest Publications
- 30 April 2008
- Published by Elsevier in Journal of Surgical Research
- Vol. 145 (2) , 205-213
Review of Various Techniques of Pancreas Transplantation in Rat Model
- 30 April 2008
- Published by Elsevier in Journal of Surgical Research
- Vol. 145 (2) , 205-213
Review of Various Techniques of Pancreas Transplantation in Rat Model
- 7 November 2006
- Published by Wiley in Clinical Transplantation
- Vol. 20 (s17) , 80-84
Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation
Non‐compliance in solid transplantation recipients is a major factor in acute graft rejection, which influences patient survival. Nowadays, tacrolimus is one of the most widely used immunosuppressant agents together with cyclosporine following kidney and liver transplantation with a standardized twice‐daily dosing regimen. To improve the patients’ compliance to the prescribed immunosuppressive therapy, FK506E (MR4), a modified release (MR) oral dosage form of tacrolimus has been developed for a once‐daily dosing regimen. This report reviews the most recent results of clinical trials with MR tacrolimus after kidney and liver transplantation.
- 7 November 2006
- Published by Wiley in Clinical Transplantation
- Vol. 20 (s17) , 80-84
Review of the clinical experience with a modified release form of tacrolimus [FK506E (MR4)] in transplantation
Non‐compliance in solid transplantation recipients is a major factor in acute graft rejection, which influences patient survival. Nowadays, tacrolimus is one of the most widely used immunosuppressant agents together with cyclosporine following kidney and liver transplantation with a standardized twice‐daily dosing regimen. To improve the patients’ compliance to the prescribed immunosuppressive therapy, FK506E (MR4), a modified release (MR) oral dosage form of tacrolimus has been developed for a once‐daily dosing regimen. This report reviews the most recent results of clinical trials with MR tacrolimus after kidney and liver transplantation.
- Open Access
Characterization of FAMPAC, a newly identified human pancreatic carcinoma cell line with a hereditary background
BACKGROUND A novel pancreatic carcinoma cell line, FAMPAC, was identified from investigation of poorly differentiated pancreatic adenocarcinoma cells found in a patient with a familial predisposition to pancreatic carcinoma. A gene responsible for familial pancreatic carcinoma has not been identified to date. METHODS The FAMPAC cell line was characterized by its morphology, growth rate, tumorigenicity, and chromosomal analysis. Three known tumor suppressor genes, p16/CDKN2, BRCA2, and p53, all of which are important in the development of pancreatic carcinoma and frequently are involved in a variety of cancer syndromes, were analyzed. RESULTS FAMPAC cells grew as an adhering monolayer in culture medium supplemented with 10% fetal bovine serum and formed tumors rapidly in nude mice. The doubling time ranged from 24 to 48 hours. Karyotype analysis demonstrated the complexity of chromosomal deletions and rearrangements. The cells were negative for ductal differentiation markers such as cytokeratin 7 and MUC1, indicating poor differentiation. Analysis of FAMPAC cells revealed overexpression of the mutated p53 gene (exon 5, codon 175: CGC → CAC), the presence of a homozygous deletion in the p16 gene, and the presence of wild‐type BRCA2 in the tested hot spots. CONCLUSIONS To the authors' knowledge, FAMPAC is the first established human pancreatic carcinoma cell line associated with a familial background. FAMPAC is a tumorigenic cell line with a complex molecular pattern of mutations. These findings may be useful in understanding the mechanisms responsible for the development of sporadic or hereditary forms of pancreatic carcinoma. Cancer 2004. © 2004 American Cancer Society.
Open AccessCharacterization of FAMPAC, a newly identified human pancreatic carcinoma cell line with a hereditary background
BACKGROUND A novel pancreatic carcinoma cell line, FAMPAC, was identified from investigation of poorly differentiated pancreatic adenocarcinoma cells found in a patient with a familial predisposition to pancreatic carcinoma. A gene responsible for familial pancreatic carcinoma has not been identified to date. METHODS The FAMPAC cell line was characterized by its morphology, growth rate, tumorigenicity, and chromosomal analysis. Three known tumor suppressor genes, p16/CDKN2, BRCA2, and p53, all of which are important in the development of pancreatic carcinoma and frequently are involved in a variety of cancer syndromes, were analyzed. RESULTS FAMPAC cells grew as an adhering monolayer in culture medium supplemented with 10% fetal bovine serum and formed tumors rapidly in nude mice. The doubling time ranged from 24 to 48 hours. Karyotype analysis demonstrated the complexity of chromosomal deletions and rearrangements. The cells were negative for ductal differentiation markers such as cytokeratin 7 and MUC1, indicating poor differentiation. Analysis of FAMPAC cells revealed overexpression of the mutated p53 gene (exon 5, codon 175: CGC → CAC), the presence of a homozygous deletion in the p16 gene, and the presence of wild‐type BRCA2 in the tested hot spots. CONCLUSIONS To the authors' knowledge, FAMPAC is the first established human pancreatic carcinoma cell line associated with a familial background. FAMPAC is a tumorigenic cell line with a complex molecular pattern of mutations. These findings may be useful in understanding the mechanisms responsible for the development of sporadic or hereditary forms of pancreatic carcinoma. Cancer 2004. © 2004 American Cancer Society.
- Open Access
- 1 July 2003
- Published by S. Karger AG in Digestive Surgery
- Vol. 20 (4) , 339-382
Inflammatory Bowel Disease Principles and Practice
- 1 July 2003
- Published by S. Karger AG in Digestive Surgery
- Vol. 20 (4) , 339-382
Open AccessInflammatory Bowel Disease Principles and Practice
- 30 April 2003
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , A822
Pancreatic fistula after pancreatic head resection: A problem of the past?
- 30 April 2003
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , A822
Pancreatic fistula after pancreatic head resection: A problem of the past?
- Open Access
- 14 March 2003
- Published by Wiley in International Journal of Cancer
- Vol. 105 (4) , 506-511
Radiation-induced leukocyte adhesion to endothelium in normal pancreas and in pancreatic carcinoma of the rat
- 14 March 2003
- Published by Wiley in International Journal of Cancer
- Vol. 105 (4) , 506-511
Open AccessRadiation-induced leukocyte adhesion to endothelium in normal pancreas and in pancreatic carcinoma of the rat
- 30 April 2000
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A529-529
In vivo adenovirus mediated gene transfer of the Eschericha coli cytosine meaminase gene to pancreatic tumours induces chemosensitivity to 5-fluorocytosine
- 30 April 2000
- Published by Elsevier in Gastroenterology
- Vol. 118 (4) , A529-529
In vivo adenovirus mediated gene transfer of the Eschericha coli cytosine meaminase gene to pancreatic tumours induces chemosensitivity to 5-fluorocytosine